Abstract

This study contains clinical efficacy of bevacizumab in conjunction with oxaliplatin and capecitabine in managing metastatic colorectal cancer. The study population consisted of 150 individuals diagnosed with metastatic colorectal cancer who sought medical care at our hospital between May 2020 and May 2022. These participants were randomly assigned to the observation group or the control group, each comprising 75 individuals. The control group received chemotherapy with the capecitabine plus oxaliplatin regimen, while the observation group received bevacizumab in conjunction with the capecitabine plus oxaliplatin regimen. In each treatment cycle, which lasted 21 d, both groups received a total of four cycles of chemotherapy. The evaluation included the determination of the objective response rate, disease control rate, Karnofsky performance status, tumor markers, and adverse reactions in both groups. In terms of the objective response rate (66.67 %) and the disease control rate (94.67 %), the observation group outperformed the control group, whose corresponding rates were 45.33 % and 74.67 % respectively (p<0.05). Significant improvements in Karnofsky performance status scores were observed in both groups after treatment, with the observation group exhibiting a more pronounced increase as opposed to the control group (p<0.05). In terms of the observed adverse reactions, the observation group displayed a remarkably lower prevalence of fatigue and liver function damage in contrast to the control group. By utilizing a combined treatment of bevacizumab, oxaliplatin, and capecitabine, individuals with metastatic colorectal cancer can experience improvements in their objective response rate and disease control rate, enhancements in their functional status scores, and reductions in the levels of serum tumor markers. The safety profile of the treatment regimen is comparable to, or even superior to the conventional approach, making it a worthwhile candidate for further promotion and application.